Pain medication company JanOne Inc (Nasdaq:JAN) stated on Thursday that it has begun the production of JAN101 under Current Good Manufacturing Practices (cGMP) for its upcoming Phase 2b trials for treating Peripheral Artery Disease (PAD) as well as a potential treatment for Covid-19 vascular complications following the successful prototype and engineering batches and positive stability data.
The company added that the Phase 2b trial is expected to begin in early 2021. The initial production batch will be 250,000 sustained release tablets and matching placebos. PAD presents a large market opportunity as there currently are no effective treatments for the disease.
According to the company, JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow. It is highly selective, acting only in damaged tissue.
Under the company's animal studies, the sodium nitrite promoted blood vessel growth and function, prevents tissue inflammation and necrosis and prevents diabetic nephropathy. Additionally, three human clinical studies showed sodium nitrite significantly reduces pain.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins